FY2024 Earnings Forecast for LSTA Issued By HC Wainwright

Lisata Therapeutics, Inc. (NASDAQ:LSTA) – HC Wainwright lifted their FY2024 EPS estimates for Lisata Therapeutics in a research report issued on Thursday, November 21st. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($2.64) per share for the year, up from their previous forecast of ($2.99). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Lisata Therapeutics’ current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for Lisata Therapeutics’ Q4 2024 earnings at ($0.79) EPS, FY2025 earnings at ($1.83) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.41) EPS and FY2028 earnings at ($1.26) EPS.

Lisata Therapeutics Price Performance

NASDAQ LSTA opened at $2.88 on Monday. The company has a market cap of $24.18 million, a price-to-earnings ratio of -1.15 and a beta of 1.22. The stock’s fifty day moving average price is $2.93 and its 200 day moving average price is $3.09. Lisata Therapeutics has a 1 year low of $2.05 and a 1 year high of $3.83.

Lisata Therapeutics (NASDAQ:LSTA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.16. During the same quarter last year, the business posted ($0.65) EPS.

Hedge Funds Weigh In On Lisata Therapeutics

An institutional investor recently raised its position in Lisata Therapeutics stock. Dimensional Fund Advisors LP raised its holdings in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 17,336 shares of the company’s stock after acquiring an additional 5,639 shares during the period. Dimensional Fund Advisors LP owned approximately 0.21% of Lisata Therapeutics worth $60,000 at the end of the most recent quarter. Institutional investors and hedge funds own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.